-+ 0.00%
-+ 0.00%
-+ 0.00%

Karyopharm Therapeutics Q4 EPS $(5.71) Misses $(1.99) Estimate, Sales $34.079M Miss $35.112M Estimate

Benzinga·02/12/2026 12:33:28
Listen to the news
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(5.71) per share which missed the analyst consensus estimate of $(1.99) by 186.36 percent. This is a 58.61 percent decrease over losses of $(3.60) per share from the same period last year. The company reported quarterly sales of $34.079 million which missed the analyst consensus estimate of $35.112 million by 2.94 percent. This is a 11.58 percent increase over sales of $30.542 million the same period last year.